Literature DB >> 31940492

FBXW7 Confers Radiation Survival by Targeting p53 for Degradation.

Danrui Cui1, Xiufang Xiong2, Jianfeng Shu1, Xiaoqing Dai1, Yi Sun3, Yongchao Zhao4.   

Abstract

The tumor suppressor p53 plays a critical role in integrating a wide variety of stress responses. Therefore, p53 levels are precisely regulated by multiple ubiquitin ligases. In this study, we report that FBXW7, a substrate recognition component of the SKP1-CUL1-F-box (SCF) E3 ligase, interacts with and targets p53 for polyubiquitination and proteasomal degradation after exposure to ionizing radiation or etoposide. Mechanistically, DNA damage activates ATM to phosphorylate p53 on Ser33 and Ser37, which facilitates the FBXW7 binding and subsequent p53 degradation by SCFFBXW7. Inactivation of ATM or SCFFBXW7 by small molecular inhibitors or genetic knockdown/knockout approaches extends the p53 protein half-life upon DNA damage in an MDM2-independent manner. Biologically, FBXW7 inactivation sensitizes cancer cells to radiation or etoposide by stabilizing p53 to induce cell-cycle arrest and apoptosis. Taken together, our study elucidates a mechanism by which FBXW7 confers cancer cell survival during radiotherapy or chemotherapy via p53 targeting.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ATM; CRL; DNA damage; E3 ligase; FBXW7; SCF; degradation; p53; radiosensitivity; ubiquitination

Mesh:

Substances:

Year:  2020        PMID: 31940492     DOI: 10.1016/j.celrep.2019.12.032

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  15 in total

1.  Early growth response-1 is a new substrate of the GSK3β-FBXW7 axis.

Authors:  Lu Yin; Jiagui Zhang; Yi Sun
Journal:  Neoplasia       Date:  2022-10-11       Impact factor: 6.218

Review 2.  Chromatin Ubiquitination Guides DNA Double Strand Break Signaling and Repair.

Authors:  Ksenia G Kolobynina; Alexander Rapp; M Cristina Cardoso
Journal:  Front Cell Dev Biol       Date:  2022-07-05

3.  A small-molecule Skp1 inhibitor elicits cell death by p53-dependent mechanism.

Authors:  Muzammal Hussain; Yongzhi Lu; Muqddas Tariq; Hao Jiang; Yahai Shu; Shuang Luo; Qiang Zhu; Jiancun Zhang; Jinsong Liu
Journal:  iScience       Date:  2022-06-14

4.  Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer.

Authors:  Hao Lin; Liang Zhang; Caihua Zhang; Pengpeng Liu
Journal:  J Cell Mol Med       Date:  2020-06-25       Impact factor: 5.310

Review 5.  F-Box Proteins and Cancer.

Authors:  Kanae Yumimoto; Yuhei Yamauchi; Keiichi I Nakayama
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

6.  p53 and FBXW7: Sometimes Two Guardians Are Worse than One.

Authors:  María Galindo-Moreno; Servando Giráldez; M Cristina Limón-Mortés; Alejandro Belmonte-Fernández; Carmen Sáez; Miguel Á Japón; Maria Tortolero; Francisco Romero
Journal:  Cancers (Basel)       Date:  2020-04-16       Impact factor: 6.639

7.  Nuclear ErbB2 represses DEPTOR transcription to inhibit autophagy in breast cancer cells.

Authors:  Yanli Bi; Longyuan Gong; Pengyuan Liu; Xiufang Xiong; Yongchao Zhao
Journal:  Cell Death Dis       Date:  2021-04-14       Impact factor: 8.469

8.  Protein tyrosine phosphatase receptor type D gene promotes radiosensitivity via STAT3 dephosphorylation in nasopharyngeal carcinoma.

Authors:  Yanling Lin; Xiaohan Zhou; Kaifan Yang; Yuting Chen; Lingzhi Wang; Wenxiao Luo; Yujiang Li; Jinrong Liao; Yingtong Zhou; Yiming Lei; Yanting Zhang; Dehua Wu; Longmei Cai
Journal:  Oncogene       Date:  2021-04-06       Impact factor: 9.867

Review 9.  The role of ubiquitination and deubiquitination in cancer metabolism.

Authors:  Tianshui Sun; Zhuonan Liu; Qing Yang
Journal:  Mol Cancer       Date:  2020-10-01       Impact factor: 27.401

Review 10.  Ubiquitin signaling in cell cycle control and tumorigenesis.

Authors:  Fabin Dang; Li Nie; Wenyi Wei
Journal:  Cell Death Differ       Date:  2020-10-31       Impact factor: 12.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.